Harvard Bioscience (FRA:HBI0) Beneish M-Score: -2.96 (As of Jun. 26, 2026)


FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
48 GF Score
Price €4.08
GF Value €13.30
! 6 Warning Signs
View Full Analysis

What is Harvard Bioscience Beneish M-Score?

Harvard Bioscience FRA:HBI0 48 Beneish M-Score is -2.96 as of Jun. 26, 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 48/100 and a GF Value™ of €13.30. The stock has 6 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Harvard Bioscience ranks better than 76.24% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.96 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Harvard Bioscience's Beneish M-Score or its related term are showing as below:

FRA:HBI0' s Beneish M-Score Range Over the Past 10 Years
Min: -3.85   Med: -2.95   Max: -2.33
Current: -2.96

During the past 13 years, the highest Beneish M-Score of Harvard Bioscience was -2.33. The lowest was -3.85. And the median was -2.95.


Harvard Bioscience Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience Beneish M-Score Chart

Harvard Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.33 -3.04 -3.09 -3.01 -3.44

Harvard Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -3.83 -3.85 -3.44 -2.96

FRA:HBI0 vs FEMY, RVP, MLSS: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Beneish M-Score falls into.


FRA:HBI0
48GF Score
Harvard Bioscience Inc FRA:HBI0
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Harvard Bioscience for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1671+0.528 * 0.9772+0.404 * 0.8542+0.892 * 0.8663+0.115 * 1.1184
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9388+4.679 * -0.104901-0.327 * 1.0826
=-3.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €12.61 Mil.
Revenue was 17.953 + 20.27 + 17.544 + 17.73 = €73.50 Mil.
Gross Profit was 10.591 + 12.103 + 10.242 + 9.999 = €42.94 Mil.
Total Current Assets was €41.07 Mil.
Total Assets was €67.42 Mil.
Property, Plant and Equipment(Net PPE) was €10.03 Mil.
Depreciation, Depletion and Amortization(DDA) was €4.85 Mil.
Selling, General, & Admin. Expense(SGA) was €31.67 Mil.
Total Current Liabilities was €20.64 Mil.
Long-Term Debt & Capital Lease Obligation was €36.82 Mil.
Net Income was -2.962 + -2.431 + -1.049 + -1.978 = €-8.42 Mil.
Non Operating Income was -0.554 + -2.368 + -0.352 + -0.732 = €-4.01 Mil.
Cash Flow from Operations was -0.573 + -0.082 + 0.924 + 2.389 = €2.66 Mil.
Total Receivables was €12.47 Mil.
Revenue was 20.141 + 23.451 + 19.795 + 21.457 = €84.84 Mil.
Gross Profit was 11.27 + 13.381 + 11.501 + 12.28 = €48.43 Mil.
Total Current Assets was €41.53 Mil.
Total Assets was €73.82 Mil.
Property, Plant and Equipment(Net PPE) was €11.37 Mil.
Depreciation, Depletion and Amortization(DDA) was €6.52 Mil.
Selling, General, & Admin. Expense(SGA) was €38.94 Mil.
Total Current Liabilities was €51.43 Mil.
Long-Term Debt & Capital Lease Obligation was €6.69 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.605 / 73.497) / (12.468 / 84.844)
=0.171504 / 0.146952
=1.1671

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(48.432 / 84.844) / (42.935 / 73.497)
=0.570836 / 0.584174
=0.9772

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (41.069 + 10.033) / 67.416) / (1 - (41.534 + 11.37) / 73.816)
=0.24199 / 0.283299
=0.8542

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=73.497 / 84.844
=0.8663

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.52 / (6.52 + 11.37)) / (4.85 / (4.85 + 10.033))
=0.364449 / 0.325875
=1.1184

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.667 / 73.497) / (38.941 / 84.844)
=0.430861 / 0.458972
=0.9388

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((36.823 + 20.641) / 67.416) / ((6.688 + 51.433) / 73.816)
=0.852379 / 0.787377
=1.0826

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-8.42 - -4.006 - 2.658) / 67.416
=-0.104901

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Harvard Bioscience has a M-score of -3.01 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.96 mean?
Harvard Bioscience (FRA:HBI0) has a Beneish M-Score of -2.96 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #182 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 23.8%.
Is Harvard Bioscience's Beneish M-Score too high?
Harvard Bioscience's current Beneish M-Score is -2.96. Based on the distribution chart, Harvard Bioscience ranks #182 out of 766 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Beneish M-Score compare to FEMY and RVP?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #182 out of 766 companies for Beneish M-Score. This places Harvard Bioscience in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current Beneish M-Score is -2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Beneish M-Score of -2.96. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current Beneish M-Score is -2.96. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Beneish M-Score is -2.96 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.

Key valuation signals for FRA:HBI0:

  • Beneish M-Score: -2.96
  • GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score

Get the complete analysis for FRA:HBI0

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€13.30
GF Value